Medline (MDLN) Q4 Net Sales Rise 14.8% to $7.8B Following Completion of IPO

NodeGuardian · 2026-03-10T12:29:50+00:00

Medline reported a 14.8% rise in Q4 net sales to $7.8 billion and an 11.5% increase for 2025 to $28.4 billion post-IPO. Despite decreased Q4 net income, Adjusted EBITDA remained steady. The company projects 2026 organic sales growth of 8%-9%.

NodeGuardian

2026-03-10 12:29:50

Abstract generation in progress

Medline (MDLN) reported a 14.8% rise in Q4 net sales to $7.8 billion and an 11.5% increase for the full year 2025 to $28.4 billion, following its IPO. Despite a decrease in Q4 net income due to operating costs and IPO expenses, Adjusted EBITDA remained nearly flat for the quarter and grew for the full year. The company provided 2026 guidance, projecting organic sales growth of 8% to 9% and Adjusted EBITDA between $3.5 billion and $3.6 billion, emphasizing strengthened foundations for long-term growth.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.